Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
J Biol Chem ; 298(5): 101876, 2022 05.
Article in English | MEDLINE | ID: mdl-35358513

ABSTRACT

Deoxyguanosine kinase (dGK) is reported responsible for the phosphorylation of deoxyadenosine (dA) and deoxyguanosine (dG) in the mitochondrial purine salvage pathway. Antiviral nucleoside analogs known as nucleoside reverse transcriptase inhibitors (NRTIs) must be phosphorylated by host enzymes for the analog to become active. We address the possibility that NRTI purine analogs may be competitive inhibitors of dGK. From a group of such analogs, we demonstrate that entecavir (ETV) competitively inhibited the phosphorylation of dG and dA in rat mitochondria. Mitochondria from the brain, heart, kidney, and liver showed a marked preference for phosphorylation of dG over dA (10-30-fold) and ETV over dA (2.5-4-fold). We found that ETV inhibited the phosphorylation of dG with an IC50 of 15.3 ± 2.2 µM and that ETV and dG were both potent inhibitors of dA phosphorylation with IC50s of 0.034 ± 0.007 and 0.028 ± 0.006 µM, respectively. In addition, the phosphorylation of dG and ETV followed Michaelis-Menten kinetics and each competitively inhibited the phosphorylation of the other. We observed that the kinetics of dA phosphorylation were strikingly different from those of dG phosphorylation, with an exponentially lower affinity for dGK and no effect of dA on dG or ETV phosphorylation. Finally, in an isolated heart perfusion model, we demonstrated that dG, dA, and ETV were phosphorylated and dG phosphorylation was inhibited by ETV. Taken together, these data demonstrate that dGK is inhibited by ETV and that the primary role of dGK is in the phosphorylation of dG rather than dA.


Subject(s)
Guanine , Phosphotransferases (Alcohol Group Acceptor) , Animals , Deoxyadenosines/metabolism , Deoxyadenosines/pharmacology , Deoxyguanosine , Guanine/analogs & derivatives , Mitochondria/metabolism , Phosphorylation , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Rats
2.
Antimicrob Agents Chemother ; 59(10): 6328-36, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26248377

ABSTRACT

The prevention of mother-to-child transmission (MTCT) of HIV is a crucial component in HIV therapy. Nucleoside reverse transcriptase inhibitors (NRTIs), primarily 3'-azido-3'-thymidine (AZT [zidovudine]), have been used to treat both mothers and neonates. While AZT is being replaced with less toxic drugs in treating mothers in MTCT prevention, it is still commonly used to treat neonates. Problems related to mitochondrial toxicity and potential mutagenesis associated with AZT treatment have been reported in treated cohorts. Yet little is known concerning the metabolism and potential toxicity of AZT on embryonic and neonatal tissues, especially considering that the enzymes of nucleoside metabolism change dramatically as many tissues convert from hyperplastic to hypertrophic growth during this period. AZT is known to inhibit thymidine phosphorylation and potentially alter deoxynucleoside triphosphate (dNTP) pools in adults. This study examines the effects of AZT on dNTP pools, mRNA expression of deoxynucleoside/deoxynucleotide metabolic enzymes, and mitochondrial DNA levels in a neonatal rat model. Results show that AZT treatment dramatically altered dNTP pools in the first 7 days of life after birth, which normalized to age-matched controls in the second and third weeks. Additionally, AZT treatment dramatically increased the mRNA levels of many enzymes involved in deoxynucleotide synthesis and mitochondrial biogenesis during the first week of life, which normalized to age-matched controls by the third week. These results were correlated with depletion of mitochondrial DNA noted in the second week. Taken together, results demonstrated that AZT treatment has a powerful effect on the deoxynucleotide synthesis pathways that may be associated with toxicity and mutagenesis.


Subject(s)
Anti-HIV Agents/toxicity , DNA, Mitochondrial/antagonists & inhibitors , Heart/drug effects , RNA, Messenger/antagonists & inhibitors , Reverse Transcriptase Inhibitors/toxicity , Zidovudine/toxicity , Adenosine Triphosphate/antagonists & inhibitors , Adenosine Triphosphate/biosynthesis , Animals , Animals, Newborn , Cytidine Triphosphate/antagonists & inhibitors , Cytidine Triphosphate/biosynthesis , DNA Copy Number Variations/drug effects , DNA, Mitochondrial/biosynthesis , Female , Gene Expression Regulation , Guanosine Triphosphate/antagonists & inhibitors , Guanosine Triphosphate/biosynthesis , Mitochondrial Proteins/antagonists & inhibitors , Mitochondrial Proteins/genetics , Mitochondrial Proteins/metabolism , Phosphorylation/drug effects , Pregnancy , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley , Uridine Triphosphate/antagonists & inhibitors , Uridine Triphosphate/biosynthesis
3.
Antimicrob Agents Chemother ; 59(1): 178-85, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25331703

ABSTRACT

Prolonged treatment with the oxazolidinone linezolid is associated with myelosuppression, lactic acidosis, and neuropathies, toxicities likely caused by impairment of mitochondrial protein synthesis (MPS). To evaluate the potential of the novel oxazolidinone tedizolid to cause similar side effects, nonclinical and pharmacokinetic assessments were conducted. In isolated rat heart mitochondria, tedizolid inhibited MPS more potently than did linezolid (average [± standard error of the mean] 50% inhibitory concentration [IC50] for MPS of 0.31 ± 0.02 µM versus 6.4 ± 1.2 µM). However, a rigorous 9-month rat study comparing placebo and high-dose tedizolid (resulting in steady-state area under the plasma concentration-time curve values about 8-fold greater than those with the standard therapeutic dose in humans) showed no evidence of neuropathy. Additional studies explored why prolonged, high-dose tedizolid did not cause these mitochondriopathic side effects despite potent MPS inhibition by tedizolid. Murine macrophage (J774) cell fractionation studies found no evidence of a stable association of tedizolid with eukaryotic mitochondria. Monte Carlo simulations based on population pharmacokinetic models showed that over the course of a dosing interval using standard therapeutic doses, free plasma concentrations fell below the respective MPS IC50 in 84% of tedizolid-treated patients (for a median duration of 7.94 h) and 38% of linezolid-treated patients (for a median duration of 0 h). Therapeutic doses of tedizolid, but not linezolid, may therefore allow for mitochondrial recovery during antibacterial therapy. The overall results suggest that tedizolid has less potential to cause myelosuppression and neuropathy than that of linezolid during prolonged treatment courses. This, however, remains a hypothesis that must be confirmed in clinical studies.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Linezolid/pharmacokinetics , Mitochondria/drug effects , Oxazolidinones/pharmacokinetics , Tetrazoles/pharmacokinetics , Animals , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/pharmacology , Drug Evaluation, Preclinical/methods , Female , Humans , In Vitro Techniques , Linezolid/adverse effects , Linezolid/pharmacology , Male , Mice , Mitochondria/metabolism , Mitochondrial Proteins/biosynthesis , Monte Carlo Method , Neurotoxicity Syndromes/etiology , Oxazolidinones/adverse effects , Oxazolidinones/pharmacology , Rats, Inbred LEC , Tetrazoles/adverse effects , Tetrazoles/pharmacology , Toxicity Tests, Chronic/methods
4.
J Biol Chem ; 290(4): 2034-41, 2015 Jan 23.
Article in English | MEDLINE | ID: mdl-25505243

ABSTRACT

The primary pathway of TTP synthesis in the heart requires thymidine salvage by mitochondrial thymidine kinase 2 (TK2). However, the compartmentalization of this pathway and the transport of thymidine nucleotides are not well understood. We investigated the metabolism of [(3)H]thymidine or [(3)H]TMP as precursors of [(3)H]TTP in isolated intact or broken mitochondria from the rat heart. The results demonstrated that [(3)H]thymidine was readily metabolized by the mitochondrial salvage enzymes to TTP in intact mitochondria. The equivalent addition of [(3)H]TMP produced far less [(3)H]TTP than the amount observed with [(3)H]thymidine as the precursor. Using zidovudine to inhibit TK2, the synthesis of [(3)H]TTP from [(3)H]TMP was effectively blocked, demonstrating that synthesis of [(3)H]TTP from [(3)H]TMP arose solely from the dephosphorysynthase pathway that includes deoxyuridine triphosphatelation of [(3)H]TMP to [(3)H]thymidine. To determine the role of the membrane in TMP metabolism, mitochondrial membranes were disrupted by freezing and thawing. In broken mitochondria, [(3)H]thymidine was readily converted to [(3)H]TMP, but further phosphorylation was prevented even though the energy charge was well maintained by addition of oligomycin A, phosphocreatine, and creatine phosphokinase. The failure to synthesize TTP in broken mitochondria was not related to a loss of membrane potential or inhibition of the electron transport chain, as confirmed by addition of carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone and potassium cyanide, respectively, in intact mitochondria. In summary, these data, taken together, suggest that the thymidine salvage pathway is compartmentalized so that TMP kinase prefers TMP synthesized by TK2 over medium TMP and that this is disrupted in broken mitochondria.


Subject(s)
Mitochondria, Heart/metabolism , Myocardium/metabolism , Thymidine Kinase/metabolism , Thymidine Monophosphate/biosynthesis , Thymine Nucleotides/biosynthesis , Animals , Carbonyl Cyanide m-Chlorophenyl Hydrazone/analogs & derivatives , Carbonyl Cyanide m-Chlorophenyl Hydrazone/chemistry , Creatine Kinase/chemistry , Cytosol/metabolism , Electron Transport , Female , Membrane Potential, Mitochondrial , Oligomycins/chemistry , Phosphocreatine/chemistry , Phosphorylation , Potassium Cyanide/chemistry , Rats , Rats, Sprague-Dawley , Thymidine/metabolism , Zidovudine/pharmacology
5.
J Neurochem ; 122(1): 126-37, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22530558

ABSTRACT

The goal of this project was to characterize deoxypyrimidine salvage pathways used to maintain deoxynucleoside triphosphate pools in isolated brain mitochondria and to determine the extent that antiviral pyrimidine analogs utilize or affect these pathways. Mitochondria from rat brains were incubated in media with labeled and unlabeled deoxynucleosides and deoxynucleoside analogs. Products were analyzed by HPLC coupled to an inline UV monitor and liquid scintillation counter. Isolated mitochondria transported thymidine and deoxycytidine into the matrix, and readily phosphorylated both of these to mono-, di-, and tri-phosphate nucleotides. Rates of phosphorylation were much higher than rates observed in mitochondria from heart and liver. Deoxyuridine was phosphorylated much more slowly than thymidine and only to dUMP. 3'-azido-3'-deoxythymidine, zidovudine (AZT), an antiviral thymidine analog, was phosphorylated to AZT-MP as readily as thymidine was phosphorylated to TMP, but little if any AZT-DP or AZT-TP was observed. AZT at 5.5 ± 1.7 µM was shown to inhibit thymidine phosphorylation by 50%, but was not observed to inhibit deoxycytidine phosphorylation except at levels > 100 µM. Stavudine and lamivudine were inert when incubated with isolated brain mitochondria. The kinetics of phosphorylation of thymidine, dC, and AZT were significantly different in brain mitochondria compared to mitochondria from liver and heart.


Subject(s)
Brain/ultrastructure , Mitochondria/drug effects , Mitochondria/metabolism , Pyrimidine Nucleosides/metabolism , Pyrimidine Nucleosides/pharmacology , Zidovudine/metabolism , Animals , Chromatography, High Pressure Liquid , Deoxycytidine/metabolism , Deoxyuridine/metabolism , Dose-Response Relationship, Drug , Kinetics , Male , Nucleotidases/metabolism , Phosphorylation/drug effects , Phosphorylation/physiology , Rats , Rats, Sprague-Dawley , Stavudine/metabolism , Stavudine/pharmacology , Thymidine/metabolism , Time Factors , Tritium/metabolism
6.
Antivir Ther ; 15(4): 587-97, 2010.
Article in English | MEDLINE | ID: mdl-20587852

ABSTRACT

BACKGROUND: The metabolism of pyrimidine deoxynucleosides and nucleoside reverse transcriptase inhibitors has been studied in growing cells. However, many of these drugs are associated with mitochondrial toxicities observed in non-replicating tissues, such as in the heart, where their metabolism has not been investigated. METHODS: The aims of this study were twofold. The first was to investigate the metabolism of the thymidine analogues 3'-azido-3'deoxythymidine (AZT) and 2',3'-didehydrodideoxy-thymidine (d4T), and the deoxycytidine (dCyd) analogues 2'-deoxy-3'-thiacytidine (3TC) and 2',3'-dideoxycytidine (ddC) with regard to phosphorylation and breakdown. The second was to investigate their potential effects, singly or in combination with AZT, on metabolism of the naturally occurring deoxynucleosides in the perfused rat heart and in isolated heart mitochondria. RESULTS: The analogue d4T was not metabolized in perfused heart or in isolated mitochondria, and had no effect on either thymidine or dCyd metabolism. The dCyd analogues were both phosphorylated in perfused heart to the triphosphate, but only at the limit of detection and they were not phosphorylated in isolated mitochondria. Neither ddC nor 3TC had any effect on thymidine or dCyd metabolism in either perfused heart or in isolated mitochondria. AZT has been previously shown to inhibit thymidine phosphorylation. When d4T, 3TC or ddC were given with AZT, only ddC caused a significant further decrease in thymidine phosphorylation. CONCLUSIONS: These results indicate that with the exception of the competition between AZT and thymidine, there was little competition for phosphorylation among and between these other nucleoside reverse transcriptase inhibitors and the naturally occurring deoxynucleosides in cardiac tissue and isolated heart mitochondria.


Subject(s)
Anti-HIV Agents/chemistry , Anti-HIV Agents/metabolism , Mitochondria, Heart/metabolism , Myocardium/metabolism , Reverse Transcriptase Inhibitors/chemistry , Reverse Transcriptase Inhibitors/metabolism , Animals , Anti-HIV Agents/pharmacology , Deoxycytidine/analogs & derivatives , Deoxycytidine/metabolism , Deoxycytidine/pharmacology , Male , Mitochondria, Heart/drug effects , Myocardium/ultrastructure , Nucleosides/chemistry , Nucleosides/metabolism , Nucleosides/pharmacology , Perfusion , Phosphorylation , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Inhibitors/pharmacology , Stavudine/metabolism , Stavudine/pharmacology , Thymidine/analogs & derivatives , Thymidine/metabolism , Thymidine/pharmacology , Zalcitabine/metabolism , Zalcitabine/pharmacology , Zidovudine/metabolism , Zidovudine/pharmacology
7.
Biochem J ; 422(3): 513-20, 2009 Aug 27.
Article in English | MEDLINE | ID: mdl-19558366

ABSTRACT

In adult non-replicating tissues such as heart, demand for dNTPs (deoxynucleoside triphosphates) is low but essential for mitochondrial DNA replication and nuclear DNA repair. dNTPs may be synthesized from salvage of deoxyribonucleosides or by reduction of ribonucleotides. We have hypothesized that the cardiac mitochondrial toxicity of the nucleoside analogue AZT (3'-azido-3'-deoxythymidine; known as zidovudine) is caused by inhibition of thymidine kinase 2 of the salvage pathway and subsequent TTP pool depletion. The extent to which this hypothesis has merit depends on how much the heart relies on thymidine phosphorylation for maintenance of the TTP pool. In the present study, we used isotopic tracing to demonstrate that both TTP and dCTP are solely synthesized by phosphorylation of thymidine and deoxycytidine respectively, with no evidence for synthesis from other precursors. We have also shown that UTP and CTP are synthesized by phosphorylation of uridine and cytidine respectively, with no detectable role for the de novo pyrimidine synthesis pathway. Lastly, we have demonstrated that AZT decreased the TTP pool by 50% in 30 min of perfusion, while having no effect on other dNTPs. In summary, the present study demonstrated that adult rat heart has a limited mechanism for dCTP and TTP synthesis and thus these pools may be more sensitive than replicating cells to drugs such as AZT that affect the salvage pathway.


Subject(s)
Heart/drug effects , Perfusion , Pyrimidine Nucleotides/metabolism , Reverse Transcriptase Inhibitors/pharmacology , Zidovudine/pharmacology , Animals , Chromatography, High Pressure Liquid , Cytidine/metabolism , Cytidine Triphosphate/metabolism , Deoxyadenine Nucleotides/metabolism , Deoxycytidine/metabolism , Deoxycytosine Nucleotides/metabolism , Deoxyguanine Nucleotides/metabolism , Deoxyuridine/metabolism , In Vitro Techniques , Male , Phosphorylation/drug effects , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Inhibitors/toxicity , Thymine Nucleotides/metabolism , Uracil/metabolism , Uridine/metabolism , Uridine Monophosphate/metabolism , Uridine Triphosphate/metabolism , Zidovudine/toxicity
8.
Antimicrob Agents Chemother ; 53(3): 1252-5, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19104011

ABSTRACT

To test whether zidovudine (3'-azido-3'-deoxythymidine) (AZT) inhibition of thymidine phosphorylation causes depletion of the TTP pool resulting in mitochondrial DNA depletion, 3T3-F442a cells were differentiated in the presence of AZT and analyzed to determine mitochondrial DNA content and deoxynucleotide levels. These results suggest that AZT toxicity may not be related to deoxynucleotide pool alterations.


Subject(s)
Anti-HIV Agents/pharmacology , Cell Differentiation/drug effects , DNA, Mitochondrial/metabolism , Stavudine/pharmacology , Zidovudine/pharmacology , 3T3 Cells , Animals , Deoxyribonucleotides/analysis , Deoxyribonucleotides/metabolism , Dose-Response Relationship, Drug , Kinetics , Mice
9.
Biochem Pharmacol ; 75(8): 1610-5, 2008 Apr 15.
Article in English | MEDLINE | ID: mdl-18295188

ABSTRACT

3'-azido-3'-deoxythymidine (AZT) has been shown to be a potent inhibitor of thymidine kinase 2 in work from this laboratory. Inhibition results in decreased salvage of thymidine to TTP, which may lead to depletion of the TTP pool and result in the mitochondrial dysfunction and mt-DNA depletion observed with AZT toxicity. The effect of AZT on thymidine phosphorylation in growing cells expressing thymidine kinase 1 has not been shown. Three cell lines were used in these experiments: H9c2, derived from rat cardiomyoblasts; U-937, derived from human monocytes; and Raji, derived from human lymphoblasts. AZT inhibited growth in a concentration-dependent manner in U-937 cells, but not the other cell lines. The phosphorylation of [3H]-thymidine or [3H]-AZT was determined during log growth. All cell lines salvaged and phosphorylated thymidine to TTP, with TTP the major product. The U-937 cells had a much more active salvage pathway than the other cells. All cell lines phosphorylated AZT to the triphosphate, but the major product was AZTMP. The AZT inhibition of growth of the U-937 cells did not correlate with levels of the phosphorylated AZT. In contrast, pro-drug AZT was shown to inhibit thymidine phosphorylation in all lines with 50% inhibition concentrations (IC50) ranging from 4.4 to 21.9muM. Since the U-937 cells expressed higher activity of the salvage pathway than the other cell lines, the U-937 cells may rely more heavily on the salvage pathway for TTP synthesis, accounting for AZT inhibition of growth.


Subject(s)
Anti-HIV Agents/pharmacology , Thymidine/metabolism , Zidovudine/pharmacology , Animals , Cell Line , Cell Line, Tumor , Cell Proliferation/drug effects , Humans , Phosphorylation/drug effects , Rats , U937 Cells
10.
Antimicrob Agents Chemother ; 51(4): 1142-9, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17220403

ABSTRACT

Zidovudine (AZT; 3'-azido-3'-deoxythymidine), a thymidine analog, has been a staple of highly active antiretroviral therapy. It is phosphorylated in the host to the triphosphate and functions by inhibiting the viral reverse transcriptase. However, long-term use of AZT is linked to various tissue toxicities, including cardiomyopathy. These toxicities are associated with mitochondrial DNA depletion, which is hypothesized to be caused by AZT triphosphate inhibition of mitochondrial DNA polymerase gamma. In previous work with isolated heart mitochondria, we demonstrated that AZT phosphorylation beyond the monophosphate was not detected and that AZT itself was a potent inhibitor of thymidine phosphorylation. This suggests an alternative hypothesis in which depletion of the TTP pool may limit mitochondrial DNA replication. The present work extends these studies to the whole cell by investigating the metabolism of thymidine and AZT in the intact isolated perfused rat heart. [3H]thymidine is converted to [3H]TTP in a time- and concentration-dependent manner. The level of [3H]TMP is low, suggesting that the reaction catalyzed by thymidine kinase is the rate-limiting step in phosphorylation. [3H]AZT is converted in a time- and concentration-dependent manner to AZT monophosphate, the only phosphorylated product detected after 3 h of perfusion. Both compounds display negative cooperativity, similar to the observations with cloned and purified mitochondrial thymidine kinase 2. The presence of AZT in the perfusate inhibits the phosphorylation of [3H]thymidine with a 50% inhibitory concentration of 24+/-4 microM. These data support the hypothesis that AZT-induced mitochondrial cardiotoxicity may be caused by a limiting pool of TTP that lowers mitochondrial DNA replication.


Subject(s)
Heart/drug effects , Mitochondria, Heart/drug effects , Thymidine/metabolism , Zidovudine/pharmacology , Animals , Mitochondria, Heart/metabolism , Perfusion , Phosphorylation/drug effects , Rats , Rats, Sprague-Dawley
11.
Biochem Pharmacol ; 72(2): 239-43, 2006 Jul 14.
Article in English | MEDLINE | ID: mdl-16720018

ABSTRACT

Long-term use of 3'-azido-3'-deoxythymidine (AZT) is associated with various tissue toxicities, including hepatotoxicity and cardiomyopathy, and with mitochondrial DNA depletion. AZT-5'-triphosphate (AZTTP) is a known inhibitor of the mitochondrial DNA polymerase gamma and has been targeted as the source of the mitochondrial DNA depletion. However, in previous work from this laboratory with isolated rat heart and liver mitochondria, AZT itself was shown to be a more potent inhibitor of thymidine phosphorylation (IC50 of 7.0+/-1.0 microM AZT in heart mitochondria and of 14.4+/-2.6 microM AZT in liver mitochondria) than AZTTP is of polymerase gamma (IC50 of >100 microM AZTTP), suggesting that depletion of mitochondrial stores of TTP may limit replication and could be the cause of the mitochondrial DNA depletion observed in tissues affected by AZT toxicity. The purpose of this work is to characterize the nature of AZT inhibition of thymidine phosphorylation in isolated rat heart and rat liver mitochondria. In both of these tissues, AZT was found to be a competitive inhibitor of the phosphorylation of thymidine to TMP, catalyzed by thymidine kinase 2. The inhibition constant (Ki) for heart mitochondria is 10.6+/-4.5 microM AZT, and for liver mitochondria Ki is 14.0+/-2.5 microM AZT. Since AZT is functioning as a competitive inhibitor, increasing thymidine concentrations may be one mechanism to overcome the inhibition and decrease AZT-related toxicity in these tissues.


Subject(s)
Mitochondria, Heart/drug effects , Mitochondria, Liver/drug effects , Thymidine/metabolism , Zidovudine/pharmacology , Animals , Chromatography, High Pressure Liquid , Mitochondria, Heart/metabolism , Mitochondria, Liver/metabolism , Phosphorylation , Rats
12.
Biochem Pharmacol ; 71(9): 1342-8, 2006 Apr 28.
Article in English | MEDLINE | ID: mdl-16472780

ABSTRACT

3'-azido-3'-deoxythymidine (AZT) is a staple of highly active antiretroviral therapy (HAART). Prior to HAART, long-term use of high-dosage AZT caused myopathy, cardiomyopathy, and hepatotoxicity, associated with mitochondrial DNA depletion. As a component of HARRT, AZT causes cytopenias and lipodystrophy. AZT-5'-triphosphate (AZTTP) is a known inhibitor of the mitochondrial polymerase gamma and has been targeted as the source of the mitochondrial DNA depletion. However, in previous work from this laboratory with isolated rat heart mitochondria, AZT phosphorylation beyond AZT-5'-monophosphate (AZTMP) was not detected. Rather, AZT was shown to be a more potent inhibitor of thymidine phosphorylation (50% inhibitory concentration (IC50) of 7.0+/-1.0 microM) than AZTTP is of polymerase gamma (IC50 of >100 microM), suggesting that depletion of mitochondrial stores of TTP may limit replication. This work has investigated whether an identical mechanism might account for the hepatotoxicity seen with long-term use of AZT. Isolated rat liver mitochondria were incubated with labeled thymidine or AZT, and the rate and extent of phosphorylation were determined by HPLC analysis of acid-soluble extracts of the incubated mitochondria. The results showed that in the phosphorylation of thymidine to TMP, liver mitochondria exhibit a higher Vmax and Km than heart mitochondria, but otherwise heart and liver mitochondria display similar kinetics. AZT is phosphorylated to AZTMP, but no further phosphorylated forms were detected. In addition, AZT inhibited the production of TTP, with an IC50 of 14.4+/-2.6 microM AZT. This is higher, but comparable to, the results seen in isolated rat heart mitochondria.


Subject(s)
Anti-HIV Agents/toxicity , Thymidine/metabolism , Zidovudine/toxicity , Animals , Chemical and Drug Induced Liver Injury , In Vitro Techniques , Kinetics , Liver Diseases/etiology , Mitochondria, Liver/drug effects , Mitochondria, Liver/metabolism , Phosphorylation/drug effects , Rats , Rats, Sprague-Dawley
13.
Cardiovasc Toxicol ; 4(2): 155-67, 2004.
Article in English | MEDLINE | ID: mdl-15371631

ABSTRACT

Antiretroviral nucleoside analogs used in highly active antiretroviral therapy (HAART) are associated with cardiovascular and other tissue toxicity associated with mitochondrial DNA depletion, suggesting a block in mitochondrial (mt)-DNA replication. Because the triphosphate forms of these analogs variably inhibit mt-DNA polymerase, this enzyme has been promoted as the major target of toxicity associated with HAART. We have used isolated mitochondria from rat heart to study the mitochondrial transport and phosphorylation of thymidine and AZT (azidothymidine, or zidovudine), a component used in HAART. We demonstrate that isolated mitochondria readily transport thymidine and phosphorylate it to thymidine 5'-triphosphate (TTP) within the matrix. Under identical conditions, AZT is phosphorylated only to AZT-5'-monophosphate (AZT-MP). The kinetics of thymidine and AZT suggest negative cooperativity of substrate interaction with the enzyme, consistent with work by others on mitochondrial thymidine kinase 2. Results show that TMP and AZT-MP are not transported across the inner membrane, suggesting that AZT-MP may accumulate with time in the matrix. Given the lack of AZT-5'-triphosphate (AZT-TP), it seems unlikely that the toxicity of AZT in the heart is mediated by AZT-TP inhibition of DNA polymerase gamma. Rather, our work shows that AZT is a potent inhibitor of thymidine phosphorylation in heart mitochondria, having an inhibitory concentration (IC)(50) of 7.0 +/- 0.9 microM. Thus, the toxicity of AZT in some tissues may be mediated by disrupting the substrate supply of TTP for mt-DNA replication.


Subject(s)
Anti-HIV Agents/pharmacokinetics , Mitochondria, Heart/metabolism , Thymidine/metabolism , Zidovudine/analogs & derivatives , Zidovudine/pharmacokinetics , Animals , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/toxicity , Antiretroviral Therapy, Highly Active , Biological Transport , Chromatography, High Pressure Liquid , DNA, Mitochondrial/metabolism , Dideoxynucleotides , In Vitro Techniques , Mitochondria, Heart/genetics , Phosphorylation , Protein Biosynthesis/drug effects , Rats , Rats, Sprague-Dawley , Thymine Nucleotides/metabolism , Time Factors , Zidovudine/administration & dosage , Zidovudine/metabolism , Zidovudine/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL
...